Wall Street analysts expect AxoGen, Inc. (NASDAQ: AXGN) to announce $23.45 million sales for the current quarter, Zacks reports. Two analysts published estimates of AxoGen’s earnings. The sales estimate is $23.90 million and the lowest is $23.00 million. AxoGen posted earnings of $28.56 million in the same quarter last year, suggesting a negative expansion rate of 17.9% year-on-year. The company is expected to announce its next quarterly earnings report on Wednesday, November 4.
On average, analysts expect AxoGen to report an annual profit of $94.50 million for the existing fiscal year, with estimates ranging from $93.50 million to $95.50 million. For next year, analysts expect the company to report sales of $111.55 million, with estimates ranging from $109.30 million to $113.80 million. Zacks Investment Research’s sales calculations average a survey of sales analysts covering AxoGen.
AxoGen (NASDAQ: AXGN) last published its quarterly earnings knowledge on Wednesday, August 5. The medical device provider reported consistent gains with a consistent percentage (EPS) of $0.20 for the quarter, exceeding the consensus estimate of $0.33 from $0.13. The company reported earnings of $22.12 million in the quarter, with $21.00 million predicted through analysts. AxoGen had a negative net margin of 28.04% and a negative return on equity of 22.08%.
AXGN has been the subject of several recent study reports. Canaccord Genuity reduced AxoGen inventories to a “retention” score and set a $12.00 value target for inventory. in a study note on Wednesday, July 1. Cantor Fitzgerald began covering AxoGen in a study note on Monday, June 15. They set a “buy” score and a target value of $16.00 for the company. SVB Leerink raised its value target on AxoGen from $13.50 to $15.50 and gave the inventory a “top performance” score on a study note on Thursday, August 6. BTIG Research reaffirmed a “retention” score on AxoGen inventories in a study report on Wednesday, August 5. Finally, BidaskClub reduced AxoGen from a “hold” score to a “sell” note in a study report on Friday. One study analyst rated the inventory with a sales note, two issued a retention note, and 3 assigned an acquisition score to the company. Lately, the inventory has an average score of “Keep” and a target consensus value of $16.13.
The NASDAQ AXGN opened at $10.89 on Thursday. The company has an average cell phone value of 50 days of $11.55 and an average 200-day moving value of $10.49. AxoGen has a minimum of 52 weeks of $7.16 and a maximum of 52 weeks of $18.84. The company has an existing ratio of 10.00, an immediate ratio of 9.09 and a debt ratio of 0.27.
The hedging budget and other institutional investors have recently increased or reduced their equity shares. Rhumbline Advisers increased its stake in AxoGen to 2.3% in the first quarter. Rhumbline Advisers now owns 46,125 medical device provider shares valued at $480,000 after earning another 1,030 shares during the period. Bank Corp. increased its stake in AxoGen to 7.3% this quarter. Bank Corp. it now owns 18,984 shares of the medical device provider valued at $175,000 after buying another 1,284 shares during the period. The Swiss National Bank increased its stake in AxoGen to 1.9% in the first quarter. The Swiss National Bank now holds 68,900 shares of the medical device provider valued at $717,000 after buying another 1,300 shares during the period. Perkins Capital Management Inc. increased its stake in AxoGen’s shares by 0.5% in the first quarter. Perkins Capital Management Inc. now holds 298,240 medical device provider shares valued at $3,102,000 after buying another 1,450 shares during the period. Finally, Mitsubishi UFJ Trust – Banking Corp. increased its share of AxoGen shares to 0.4% in the first quarter. Mitsubishi UFJ Trust – Banking Corp now holds 384,380 medical device provider shares valued at $3,998,000 after buying another 1,560 shares during the period. Institutional investors and the hedging budget own 82.54% of the company’s shares.
AxoGen company profile
AxoGen, Inc. develops and markets surgical solutions for peripheral nerve damage. The company’s surgical responses come with Advance Nerve Graft, a treated human nerve allograft ready to use for bypass surgery for cut nerves without the comorities related to a momentary surgical site; AxoGuard Nerve Connector, an aid for co-adapting an extracellular submucosal swine matrix (ECM) for tension-free fixation of severed nerves; and AxoGuard Nerve Protector, a submucosal ecM porcine product used to wrap and protect broken peripheral nerves, as well as for nerve reconstruction while avoiding soft tissue fixation.
Get a loose copy of Zacks’ AxoGen (AXGN) report
To learn more about Zacks Investment Research’s study offerings, Zacks.com
Ryan L.Vardeman acquires 25,112 shares of BSQUARE Co. (NASDAQ: BSQR)
Penske Automotive Group, Inc. (NYSE: PAG) expects quarterly sales of $5.56 billion